Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...
Try it now — load your own PDF or use the sample: ...
The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback